Analysis of Low Frequency Protein Truncating Stop-Codon Variants and Fasting Concentration of Growth Hormone

Erik Hallengren¹,²*, Peter Almgren¹, Gunnar Engström¹, Margaretha Persson¹,², Olle Melander¹,²

¹ Department of Clinical Sciences, Lund University, Malmö, Sweden, ² Department of Internal Medicine, Skåne University Hospital, Malmö, Sweden

* Current address: Department of Clinical Sciences, Malmö, CRC, Jan Waldenströms gata 35, bldg 91, level 12, Skåne University Hospital, SE 205 02, Malmö, Sweden

* erik.hallengren@med.lu.se

Abstract

Background

The genetic background of Growth Hormone (GH) secretion is not well understood. Mutations giving rise to a stop codon have a high likelihood of affecting protein function.

Objectives

To analyze likely functional stop codon mutations that are associated with fasting plasma concentration of Growth Hormone.

Methods

We analyzed stop codon mutations in 5451 individuals in the Malmö Diet and Cancer study by genotyping the Illumina Exome Chip. To enrich for stop codon mutations with likely functional effects on protein function, we focused on those disrupting  >80% of the predicted amino acid sequence, which were carried by ≥10 individuals. Such mutations were related to GH concentration, measured with a high sensitivity assay (hs-GH) and, if nominally significant, to GH related phenotypes, using linear regression analysis.

Results

Two stop codon mutations were associated with the fasting concentration of hs-GH. rs121909305 (NP_005370.1:p.R93*) [Minor Allele Frequency (MAF) = 0.8%] in the Myosin 1A gene (MYO1A) was associated with a 0.36 (95%CI, 0.04 to 0.54; p=0.02) increment of the standardized value of the natural logarithm of hs-GH per 1 minor allele and rs35699176 (NP_067040.1:p.Q100*) in the Zink Finger protein 77 gene (ZNF77) (MAF = 4.8%) was associated with a 0.12 (95%CI, 0.02 to 0.22; p = 0.02) increase of hs-GH. The mutated high hs-GH associated allele of MYO1A was related to lower BMI (β-coefficient, -0.22; p = 0.05), waist (β-coefficient, -0.22; p = 0.04), body fat percentage (β-coefficient, -0.23; p = 0.03) and...
with higher HDL (β-coefficient, 0.23; p = 0.04). The ZNF77 stop codon was associated with height (β-coefficient, 0.11; p = 0.02) but not with cardiometabolic risk factors.

**Conclusion**

We here suggest that a stop codon of MYO1A, disrupting 91% of the predicted amino acid sequence, is associated with higher hs-GH and GH-related traits suggesting that MYO1A is involved in GH metabolism and possibly body fat distribution. However, our results are preliminary and need replication in independent populations.

**Introduction**

Growth Hormone (GH) is secreted from the anterior pituitary gland and exerts important biological actions throughout the entire life, such as protein anabolism in muscles, lipolysis in adipose tissue and regulation of glucose and lipid metabolism [1]. In healthy individuals lower values of basal GH are associated with higher values of body mass index (BMI), waist, low density lipoprotein cholesterol (LDL-C) and lower values of high density lipoprotein cholesterol (HDL-C) [2–4]. With these associations indicating a more adverse cardiovascular risk profile one might assume that GH is beneficial, however our recent results contradict this, showing that higher fasting levels of GH are associated with increased cardiovascular morbidity and mortality [2], confirming similar previous results from Maison et al [5]. With these results it would be interesting to find genetic determinants of GH and in a later phase investigate their relation to cardiovascular disease. As mentioned in our previous article [2], GH plasma concentration is relatively stable in the morning hours [6–8] and we used a high sensitivity assay for plasma GH measurements (hs-GH) able to quantify even the low normal range of GH-levels.

Genome-wide association studies (GWAS) have seen a large increase in the last few years and in 2,111 publications over 15 000 (February 2015) common single nucleotide polymorphisms (SNP) associated with complex human traits and diseases have been found [9]. Despite this tremendous amount of successful studies, a lot of the presumed heritability is still unaccounted for and it is becoming evident that GWAS targeting common genetic variants are insufficient to explain a lot of the missing heritability [10–12]. For example BMI is a polygenetic trait believed to be heritable to a degree of above 40% [11]. A recent GWAS and metabochip analysis of over 339,000 individuals found 97 loci associated with BMI, but these only explained ~3% of the phenotypic variance [10]. It is believed that the common snps genotyped today could at the most explain roughly 50% of the heritability (i.e. 20% of phenotypic variance) of BMI [10,11]. Figures for other traits such as LDL-C, HDL-C and height are roughly the same, with common snps supposed to explain 50–60% of the heritability with a theoretically infinite sample size [11,13]. Empirically, monogenic diseases are very rare but the underlying mutations are characterized by high phenotypic penetrance. Thus, it has been suggested that low frequency and rare variants (present in <5% and <1% of the population, respectively) may have large effect sizes that cannot fully be captured in traditional GWAS as the latter is designed to identify predominantly common gene variants [12,14,15], and that such low frequency and rare variants may explain part of the missing heritability. Although studies of such variants have shown larger effect sizes compared to GWAS [16–18], a larger part of the heritability still remains to be explained.
The exome chip is a chip-based array including approximately 250,000 previously identified coding variants [including missense variants, nonsense (stop codon) variants and splice site variants], the majority of which occur at low frequency (<5%) [19,20]. Most efforts to analyze the plethora of coding variants of the exome chip, have been performed using candidate gene approaches or burden tests where the latter assume that all mutations at a locus functionally affect the trait of interest [16,17,21]. This assumption is unlikely to be true and thus lead to false negative results if only one out of the many variants at a locus is in fact functional and affect the phenotype of interest [22].

We here genotyped a cohort of 5451 individuals using an exome chip and in an attempt to filter out the variants most likely to be of functional importance, focused on stop codon mutations which disrupt at least 80% of the predicted amino acid sequence of the encoded protein. Using this strategy we aimed at identifying stop codon mutations that affect fasting GH concentration, and possibly GH related phenotypes.

Specifically, we applied the following criteria: The mutation should encode a stop codon, disrupt at least 80% of the protein, have at least 10 carriers in our sample, minor allele frequency (MAF)<0.05 and a p-value of <0.05 in a linear regression model with GH.

**Methods**

The Malmö diet and cancer study (MDC) is a population-based, prospective cohort of males born between 1923 and 1945 and women born between 1923 and 1950. A total of 28,449 individuals were examined between 1991 and 1996 [23]. From this cohort a random sample, examined between November 1991 and February 1994 (n = 6103) were included in the MDC cardiovascular cohort (MDC-CC), with the primary aim to study the epidemiology of carotid artery disease [24]. The primary study cohort consists of those in which DNA was available and genotyping of the exome chip was successful (n = 5451), i.e. past our QC criteria.

All participants provided written consent and the study was approved by Regional Ethical Review Board in Lund, Sweden.

At baseline (1991–96) participants underwent a medical history, physical examination and laboratory assessment. Levels of HDL-C and total cholesterol were measured according to standard procedures at the Department of Clinical Chemistry, University Hospital of Malmö. The levels of LDL-C were calculated according to the Friedewald formula.

All samples of plasma and whole-blood were obtained after overnight fasting and samples were drawn between 7.30 am and 9.00 am. Further details about the clinical examination can be found in previous articles [2,23,24].

GH levels were measured in stored fasting plasma samples, which had been frozen to -80°C immediately at the MDC-CC baseline examination. The measurement was made with a high-sensitivity chemiluminescence sandwich immunoassay previously described (SphingoTec GmbH, Borgsdorf, Germany) [2]. Individuals with GH-value equal to 0 (n = 12) were censored in the analyses including GH as a variable.

Genotyping of the cohort was made using the HumanOmniExpressBeadChip and iScan system (Illumina, San Diego, CA, USA) analyzing 250,000 coding variants (missense variants, nonsense variants and splice site variants).

A multivariate linear regression model with log-transformed hs-GH as the dependent variable were executed for each of the stop codons and adjusted for gender and age using PLINK software [25]. The variants that fulfilled all of the following criteria were then selected for further analyses:

- MAF < 5%. In order not to catch variants that has been captured in previous GWAS-assays.
At least 10 carriers of the allele in our sample (= minor allele frequency (MAF) ≥ 0.1%) to exclude mutations that are so rare that statistical analysis is not possible.

Nonsense mutation, i.e. the variant encodes a stop codon instead of an amino acid, disrupting the protein with possibly loss-of-function for the gene. The UCSC genome browser (UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19 Assembly, http://genome.ucsc.edu/)) [26] was used to confirm the location and genetic code.

The mutation disrupts at least 80% of the protein, for example amino acid (AA) number 30 out of 289 is replaced by a stop codon. Thereby making the chances for biological relevance greater. The Uniprot Knowledgebase (http://www.uniprot.org) [27] was used as reference for the number of AA in the protein. If multiple splice variants were known to exist for the protein, this criterion had to be fulfilled in all splice variants available in the CCDS-database (Consensus coding sequences; [http://www.ncbi.nlm.nih.gov/CCDS/CcdsBrowse.cgi]) [28,29].

\( P<0.05 \) in the linear regression model for the association between the stop codon mutation and GH.

The stop codon mutations that fulfilled all of the above criteria were selected for further analysis. The number of snps available in each step is shown in Fig 1.

The following analyses were performed in SPSS (version 22.0.0, SPSS Inc, Chicago, Ill). A 2-sided P value of less than 0.05 was considered nominally significant.

We used variables known to be associated with fasting hs-GH from our previous study [2]. These were LDL-C, HDL-C, BMI, waist and body fat percentage. Height was also added since we hypothesized that it would correlate with GH. Given the difference in fasting GH concentration between the genders the variables including hs-GH were transformed into the natural logarithm and standardized separately for men and women before being used in any analysis. Multivariate regression models adjusted for sex and age were then analyzed between GH and the various variables stated above.

After selection of the stop codon variants as described above, these variants were analyzed vs the GH-associated traits in order to test if any genetic effect on hs-GH may translate into an effect on GH-related traits. Each of the GH-associated variables were entered as the dependent variable into multivariate regression models with sex, age and one stop codon mutation per model. We assumed an additive model of inheritance in all analyses. If the association snp vs GH-related trait was nominally significant we performed a mediation analysis to test whether the effect of the snp on the trait was mediated through hs-GH [30].

Results

Baseline characteristics of the participants are shown in Table 1. The individuals in whom genotyping could not be performed due to missing samples or poor call rates in the genotyping did not differ in their baseline characteristics (S1 Table).

In the multivariate adjusted linear regression models hs-GH displayed nominally significant negative associations with BMI, waist and LDL-C and nominally significant positive ones with HDL-C and height (Table 2). The \( R^2 \) was highest in the analysis for waist (6.8%) and lowest for height (0.5%).

We identified 2 stop codon mutations, fulfilling the criteria set up, with nominally significant association with hs-GH, one in the Myosin 1A gene (MYO1A) and one in the Zink Finger Protein 77 gene (ZNF77) (Table 3). Illumina cluster plots indicated that the genotyping was of good quality (S1 and S2 Figs). A total of 64 snps fulfilled the criteria set up previous to the
association test with hs-GH (S2 Table). The stop codon of MYO1A (rs121909305), which occurred at a MAF of 0.8%, replaces an arginine at amino acid position 93 with a premature stop codon (NP_005370.1:p.R93*C), thereby deleting 91% of the predicted MYO1A amino acid sequence. The stop codon of ZNF77 (rs35699176), occurred at a MAF of 4.8% and replaces a glutamine residue (NP_067040.1:p.Q100*) resulting in deletion of 82% of the predicted ZNF77 amino acid sequence. If the cut-off had been set at 50%, 2 additional stop codon variants had been added.

Presence of the minor allele was in both stop codon mutations associated with higher hs-GH (Table 3). In our material there were individuals who were both heterozygous and homozygous for the minor allele in rs35699176 (ZNF77), while no individuals were homozygous for the minor allele in rs121909305 (MYO1A).
To test if the effect of the identified stop codon mutations on hs-GH may influence GH-related traits they were related to anthropometric measures and lipoprotein levels to which we found significant relationships for fasting concentration of plasma hs-GH. The results of the linear regression models, adjusted for gender and age are shown in Table 4. The mutated high hs-GH associated allele of MYO1A was nominally related to lower BMI, waist, body fat percentage and with higher HDL. The ZNF77 stop codon variant related to higher hs-GH was positively nominally associated with height but not with anthropometric or lipoprotein traits. A mediation analysis testing the previous mentioned nominally significant traits resulted in nominal significance for hs-GH and non-significant results for the snps in all traits suggesting that the association between the snps and traits were mediated through hs-GH (S3 Table).

Discussion

We here focused exome chip analysis to variants resulting in premature stop codons disrupting the majority of the protein, thereby being likely to alter protein function. In addition, we

### Table 1. Clinical characteristics of the study population.

| Variable                        | Participants with data |
|---------------------------------|------------------------|
| Female (%)                      | 3187 (58.5)            |
| Age, mean (SD), years           | 57.5 (5.9)             |
| Body Mass Index, Mean (SD), kg/m2| 25.8 (4.0)             |
| Waist, mean (SD), cm            | 84.1 (13.0)            |
| Bodyfat percentage, mean (SD), %| 27.6 (7.1)             |
| LDL-C, mean (SD), mmol/L        | 4.20 (0.98)            |
| HDL-C, mean (SD), mmol/L        | 1.38 (0.37)            |
| Height, mean (SD), cm           | 169 (9)                |
| Growth Hormone—males, median (IQR), µg/L | 0.11 (0.06–0.33) |
| Growth Hormone—females, median (IQR), µg/L | 1.21 (0.38–3.12) |

LDL-C, Low-density lipoprotein cholesterol; HDL-C, High-density lipoprotein cholesterol

doi:10.1371/journal.pone.0128348.t001

### Table 2. Results from multiple linear regression models adjusted for sex and age examining correlations between fasting values of growth hormone and traditionally associated variables.

| Variable                        | β coefficient* | 95% CI       | P      |
|---------------------------------|----------------|--------------|--------|
| BMI†                            | -0.24          | -0.27 to -0.21 | 6.65E-56 |
| Waist                           | -0.25          | -0.28 to -0.22 | 1.72E-58 |
| Bodyfat percentage              | -0.23          | -0.26 to -0.20 | 6.15E-51 |
| HDL-C†                          | 0.19           | 0.16 to 0.22  | 1.02E-34 |
| LDL-C†                          | -0.13          | -0.16 to -0.10 | 1.11E-15 |
| Height                          | 0.04           | 0.01 to 0.07  | 0.007  |

One regression model is performed per variable with hs-GH as the dependent variable vs the variable in question, sex and age as independent variables.

* The β coefficients are expressed as the increment of standardized values of the natural logarithm of hs-GH per 1 increment of standardized values of the natural logarithm of the variable in question. Variables and hs-GH are standardized separately in men and women before being used in the combined analysis.

†Abbreviations: BMI, Body Mass Index; LDL-C, Low-density lipoprotein cholesterol; HDL-C, High-density lipoprotein cholesterol

doi:10.1371/journal.pone.0128348.t002
restricted the search to low-frequency variants (MAF < 5%), making them less likely to have been picked up by previous GWAS analyses but at the same time not being so rare that they would be impossible to statistically handle (at least 10 carriers, here corresponding to a MAF > 0.1%). Thereby we identified a premature stop codon in \textit{MYO1A} associated with higher hs-GH and lower measures of obesity as well as higher levels of HDL-C and one premature stop codon of \textit{ZNF77} associated with higher hs-GH and height. Given the large proportions of the predicted amino acid sequences of these two proteins which were deleted as a consequence of the stop codon variants (91 and 82%, respectively), it is reasonable to assume that the function of the two proteins would be reduced, rather than enhanced, however, the knowledge of

| SNP          | Gene | Mutation | Protein length | Carriers—total | Carriers—GH | MAF # | Beta* | 95%CI      | P    |
|--------------|------|----------|----------------|---------------|-------------|-------|-------|-----------|------|
| rs35699176   | ZNF77| p.Q100*  | 545            | 17/493/4940   | 13/364/3756 | 4.8%  | 0.12  | 0.02 to 0.22 | 0.02 |
| rs121909305  | MYO1A| p.R93*   | 1043           | 0/86/5365     | 0/63/4071   | 0.8%  | 0.36  | 0.04 to 0.54 | 0.02 |

*MAF < 5%, mutation giving rise to stop codon, >9 carriers in our sample, nominally significant association with hs-GH (P < 0.05), mutation disrupting > 80% of the protein and present in all splice variants.

†Original amino acid, amino acid no
‡Number of amino acids in the predicted amino acid sequence
§Number of homozygous carriers for minor allele, heterozygous and homozygous carriers for major allele respectively
¶Number of carriers in which values of hs-GH were available
#Minor allele frequency in our sample
**The β coefficients are expressed as the increment of standardized values of the natural logarithm of hs-GH per 1 minor allele. NB hs-GH is standardized separately in men and women before being used in the combined analysis.

Table 3. Stop codon mutations fulfilling the criteria previously described.

Table 4. Linear regression models adjusted for sex and age exploring the relation between various GH-associated variables and the stop codon mutations.

| SNP          | Variable | Beta* | 95%CI      | P    |
|--------------|----------|-------|-----------|------|
| rs35699176   | BMI †    | -0.033| -0.120 to 0.053 | 0.45 |
| (ZNF77)      | Bodyfat% | -0.063| -0.149 to 0.023 | 0.15 |
|              | Waist    | 0.005 | -0.081 to 0.091 | 0.91 |
|              | LDL †    | 0.009 | -0.082 to 0.101 | 0.84 |
|              | HDL †    | -0.012| -0.105 to 0.080 | 0.80 |
|              | Height   | 0.106 | 0.020 to 0.191  | 0.02 |
| rs121909305  | BMI †    | -0.216| -0.428 to -0.004 | 0.05 |
| (MYO1A)      | Bodyfat% | -0.234| -0.445 to -0.024 | 0.03 |
|              | Waist    | -0.219| -0.432 to -0.006 | 0.04 |
|              | LDL †    | -0.180| -0.403 to 0.043  | 0.11 |
|              | HDL †    | 0.234 | 0.009 to 0.459   | 0.04 |
|              | Height   | 0.020 | -0.190 to 0.230  | 0.85 |

One model is executed per variable with the variable in question as the dependent variable and the stop codon mutation, sex and age as independent variables.

*The β coefficients are expressed as the increment of standardized values of the natural logarithm of the variable per presence of 1 minor allele. The variables are standardized separately in men and women before being used in the combined analysis.

†Abbreviations: BMI, Body Mass Index; LDL-C, Low-density lipoprotein cholesterol; HDL-C, High-density lipoprotein cholesterol

Reference

PLOS ONE | DOI:10.1371/journal.pone.0128348 June 18, 2015 7 / 12
active sites and regulatory domains of the two proteins are limited, so gain of function as a result of the mutations cannot be excluded.

Although there have been reports on genetic variants in genes coding for components of the GH-system which are associated with GH-related traits, e.g. genetic variance of the GH receptor [31], studies on genetic determinants in relation to fasting GH concentration are rare. We are only aware of one previous article, in which a SNP in GH1 was found to be associated with the fasting concentration of GH [32]. Our result thus encourages not only replication efforts of the two mutations in relation to fasting GH concentration but also studies in much larger cohorts to test if the genetic elevation of GH mediated by stop codons of MYO1A and ZNF77 could be replicated and if it would be associated with risk of cardiovascular disease and mortality.

The stop codon mutation in MYO1A was interesting in the sense that it showed associations both to GH and to GH-related phenotypes. The minor allele was associated with an increase in fasting plasma GH and affected the GH-related variables as could be expected, thereby strengthening the hypothesis that it could be a genetic determinant of fasting plasma GH. A mediation analysis indicated that the effect of the mutated allele on the GH-related variables, were mediated through hs-GH and not from pleiotropic effects. Although the results are exciting, the multiple testing is an issue that requires cautious interpretation of the results. MYO1A is an unconventional myosin located on 12q13.3 and the very same stop codon mutation (rs121909305) was suggested to be responsible for autosomal dominant hearing loss in 2003 [33]. However knockout models in mice and a recent GWAS did not confirm this association and the authors in the latter concluded that MYO1A seemed “dispensable for hearing and overall non-essential” [34,35]. In the knockout mice the MYO1A protein could be identified in enterocytes and was found to be important for the composition and regulation of the brush border. However the mice did not exhibit any overt phenotype and growth and weight gain were similar to wild-type littermates [34]. The study did not focus on GH-function and it would be interesting to study the KO-mice from this perspective, with more thorough measurements of body composition and observations of life span, since the function of the GH-axis has been shown to affect life span in mice [36–38]. To our knowledge, our study is the first suggesting a connection between GH and MYO1A.

The other stop codon mutation that passed all the criteria was rs35699176, present in ZNF77, a zinc finger protein located on chromosome 19p13.3 and containing four exons encoding a 545 amino acid protein [26,27,39]. In the analyses with GH-associated phenotypes, the only association was with height, which is not one of the stronger associations with hs-GH in adults (Table 2). The variant is relatively common with a MAF of 4.8%, just passing our threshold of <0.05. This probably makes it common enough to be detectable in a GWAS and thus makes it less attractive to analyze with our approach.

Publications on this gene are scarce. One whole exome sequencing study from 2013 examining patients with fibromyalgia found that this exome variant (rs35699176) was associated with fibromyalgia based on the inheritance pattern from their parents and elevated levels of the inflammatory cytokine, IL-12 [40]. GH has previously been connected to the function of the immune system and a study of short stature non-GHD children showed that administration of GH increased levels of IL-12 [41]. A subsequent study from the same research group, examining children with GHD did not show the same effect of GH administration [42]. Thus an effect of ZNF77 on GH metabolism is a possibility, however more studies investigating this relationship are required.

Our study has several limitations. Since we are using a new approach for analyzing data from the exome chip, the method is not previously validated. We have tried to apply stringent criteria that would be easy to follow and strived to find biologically relevant mutations. By
finding association not only between the stop codon mutations and GH, but also between the mutations and a GH-related phenotype our findings have larger credibility. However they need to be replicated in a larger cohort, especially since the stop codon mutations are rare. It may be that with a similar analysis and larger sample sizes one might find additional genetic determinants of plasma GH.

The cut-off at 80% is not based on any biological finding but rather follows the logic that an early truncation ought to have a larger effect on the protein. If this had been set to 50%, 2 additional stop codon mutations had been included.

We have used $p<0.05$ as significance level and it is a risk that we due to multiple testing have encountered false positives. 64 stop codon mutations were analyzed vs hs-GH. A Bonferroni corrected $p$-value would be $0.05/64 = 0.00078$. None of the variants fulfill this and a larger study is probably necessary to achieve this significance level. This underlines the need of replicating our results in other populations.

As we pointed out in our previous study [2], the use of fasting hs-GH is not a standard clinical test and the release of GH in pulses complicates measurement. However as mentioned earlier, measurements were made in the morning when plasma GH concentration is relatively stable [6–8]. The amount of non-accepters to the initial invitation was quite large, which could make a bias selection of a more healthy population. There was no suspicion of selection bias in people not included in the genetic analysis.

If our result with the stop codon mutations in $MYO1A$ and/or $ZNF77$ being genetic determinants of plasma GH could be replicated in another study it would be interesting to further investigate if these variants are associated with an increased cardiovascular morbidity and mortality as previously suggested [2,5]. Unfortunately the current study is underpowered to answer this question.

In conclusion we here demonstrate a new way to analyze rare genetic variants from the exome chip and find that a stop codon mutation in $MYO1A$ (rs121909305) is nominally associated to the fasting level of plasma GH. A stop codon mutation in $ZNF77$ was also nominally associated to fasting plasma GH but the connection to a GH-related phenotype was weaker. Our findings need to be replicated in a larger cohort, which with morbidity data could provide new insights regarding GH and cardiovascular diseases.

Supporting Information

S1 Table. Clinical characteristics of the study population and individuals in which genotyping was not possible due to missing samples or unsuccessful genotyping. Abbreviations: LDL-C, Low-density lipoprotein cholesterol; HDL-C, High-density lipoprotein cholesterol (DOCX)

S2 Table. List of stop codon mutations fulfilling the criteria with the exception of association with hs-GH. Abbreviations: MAF, minor allele frequency. $P$ is for association with hs-GH in a linear regression model adjusted for sex and age. Carriers—number of homozygous carriers for minor allele, heterozygous and homozygous carriers for major allele respectively. Mutation shows the effect of the mutation on the transcript. (XLSX)

S3 Table. Mediation analysis of nominally significant traits. One linear regression model is executed per trait with the trait in question as the dependent variable and the stop codon mutation, hs-GH, sex and age as independent variables. The natural logarithms of the traits and of hs-GH are standardized separately in men and women. Abbreviations as
previously mentioned.

**S1 Fig. Illumina cluster plot for rs35699176.** Cluster plot showing genotyping for snp in ZNF77. NB, samples with black dots did not pass our quality criteria for genotyping and were thus excluded from the study.

**S2 Fig. Illumina cluster plot for rs121909305.** Cluster plot showing genotyping for snp in MYO1A.

**Author Contributions**

Conceived and designed the experiments: EH PA GE MP OM. Performed the experiments: EH PA GE MP OM. Analyzed the data: EH PA OM. Contributed reagents/materials/analysis tools: EH PA GE MP OM. Wrote the paper: EH PA GE MP OM. Drafting of the manuscript: EH OM. Critical revision of the manuscript for important intellectual content: EH PA GE MP OM.

**References**

1. Møller N, Jørgensen JOL (2009) Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects. Endocr Rev 30: 152–177. doi: 10.1210/er.2008-0027 PMID: 19240267

2. Hallengren E, Almgren P, Engstom G, Hedblad B, Persson M, Suhr J, et al. (2014) Fasting levels of high-sensitivity growth hormone predict cardiovascular morbidity and mortality: the Malmö Diet and Cancer study. J Am Coll Cardiol 64: 1452–1460. doi: 10.1016/j.jacc.2014.03.063 PMID: 25277616

3. Hindmarsh PC, Fall CH, Pringle PJ, Osmond C, Brook CG (1997) Peak and trough growth hormone concentrations have different associations with the insulin-like growth factor axis, body composition, and metabolic parameters. J Clin Endocrinol Metab 82: 2172–2176. PMID: 9215290

4. Miller KK, Biller BM, Lipman JG, Bradwin G, Rifai N, Klibanski A. (2005) Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk. J Clin Endocrinol Metab 90: 768–774. PMID: 15572428

5. Maison P, Balkau B, Simon D, Chanson P, Roaselin G, Eschwège E. (1998) Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. BMJ 316: 1132–1133. PMID: 9552951

6. Saini S, Hindmarsh PC, Matthews DR, Pringle PJ, Jones J, Preece MA, et al. (1991) Reproducibility of 24-hour serum growth hormone profiles in man. Clin Endocrinol (Oxf) 34: 455–462. PMID: 1889130

7. Surya S, Symons K, Rothman E, Barkan AL (2006) Complex rhythmicity of growth hormone secretion in humans. Pituitary 9: 121–125. PMID: 16845601

8. Jaffe CA, Ocampo-Lim B, Guo W, Krueger K, Sugahara I, DeMott-Friberg R, et al. (1998) Regulatory mechanisms of growth hormone secretion are sexually dimorphic. J Clin Invest 102: 153–164. PMID: 9649569

9. Hindorff LA MJ, Morales J, Junquera HA, Hall PN, Klemm AK, and Manolio TA. (2015) A Catalog of Published Genome-Wide Association Studies. Available at: http://www.genome.gov/gwasstudies. Accessed: 2015-03-25.

10. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. (2015) Genetic studies of body mass index yield new insights for obesity biology. Nature 518: 197–206. doi: 10.1038/nature14177 PMID: 25673413

11. Zaitlen N, Kraft P, Patterson N, Pasaniuc B, Bhatia G, Pollack S, et al. (2013) Using extended genealogy to estimate components of heritability for 23 quantitative and dichotomous traits. PLoS Genet 9: e1003520. doi: 10.1371/journal.pgen.1003520 PMID: 23737753

12. Bjorkegren JL, Kovacic JC, Dudley JT, Schadt EE (2015) Genome-Wide Significant Loci: How Important Are They?: Systems Genetics to Understand Heterogeneity of Coronary Artery Disease and Other Complex Disorders. J Am Coll Cardiol 65: 830–845. doi: 10.1016/j.jacc.2014.12.033 PMID: 25720628
13. Yang J, Manolio TA, Pasquale LR, Boerwinkle E, Caporaso N, Cunningham JM, et al. (2011) Genome partitioning of genetic variation for complex traits using common SNPs. Nat Genet 43: 519–525. doi: 10.1038/ng.823 PMID: 2152263.

14. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. (2009) Finding the missing heritability of complex diseases. Nature 461: 747–753. doi: 10.1038/nature08494 PMID: 19812666.

15. Lettre G (2014) Rare and low-frequency variants in human common diseases and other complex traits. J Med Genet 51: 705–714. doi: 10.1136/jmedgenet-2014-102437 PMID: 25185437.

16. Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, et al. (2014) Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 371: 22–31. doi: 10.1056/NEJMoa1307095 PMID: 24941081.

17. Do R, Stitziel NO, Won HH, Jorgensen AB, Duga S, Angelica Merlini P, et al. (2015) Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 518: 102–106. doi: 10.1038/nature13917 PMID: 25631608.

18. Wessel J, Chu AY, Willems SM, Wang S, Yaghootkar H, Brody JA, et al. (2015) Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. Nat Commun 6: 5897. doi: 10.1038/ncomms6897 PMID: 25631608.

19. Grove ML, Yu B, Cochran BJ, Haritunians T, Bis JC, Taylor KD, et al. (2013) Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium. PLoS One 8: e68095. doi: 10.1371/journal.pone.0068095 PMID: 23874508.

20. Niewergetl CM, Wineinger NE, Libiger O, Pham P, Zhang G, Baker DG, et al. (2014) Chip-based direct genotyping of coding variants in genome wide association studies: utility, issues and prospects. Gene 540: 104–109. doi: 10.1016/j.gene.2014.01.069 PMID: 24521671.

21. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A (2014) Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 371: 32–41. doi: 10.1056/NEJMoa1308027 PMID: 24941082.

22. Moutsianas L, Morris AP (2014) Methodology for the analysis of rare genetic variation in genome-wide association and re-sequencing studies of complex human traits. Brief Funct Genomics 13: 362–370. doi: 10.1093/bfgp/elu012 PMID: 24916163.

23. Berglund G, Elmstahl S, Janzon L, Larsson SA (1993) The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 233: 45–51. PMID: 8429286.

24. Rosvall M, Janzon L, Berglund G, Engstrom G, Hedblad B (2005) Incidence of stroke is related to carotid IMT even in the absence of plaque. Atherosclerosis 179: 325–331. PMID: 15777549.

25. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575. PMID: 17701901.

26. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. (2002) The human genome browser at UCSC. Genome Res 12: 996–1006. PMID: 12045153.

27. Magrane M, Consortium U (2011) UniProt Knowledgebase: a hub of integrated protein data. Database (Oxford) 2011: bar009.

28. Pruitt KD, Harrow J, Harte RA, Wallin C, Diekhans M, Maglott DR, et al. (2009) The consensus coding sequence (CCDS) project: Identifying a common protein-coding gene set for the human and mouse genomes. Genome Res 19: 1316–1323. doi: 10.1101/gr.080531.108 PMID: 19498102.

29. Farrell CM, O’Leary NA, Harte RA, Loveland JE, Wilming LG, Wallin C, et al. (2014) Current status and new features of the Consensus Coding Sequence database. Nucleic Acids Res 42: D865–872. doi: 10.1093/nar/gkt1059 PMID: 24217909.

30. Baron RM, Kenny DA (1986) The moderator–mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. Journal of Personality and Social Psychology 51: 1173–1182. PMID: 3806354.

31. Glad CA, Carlsson LM, Melander O, Almgren P, Sjostrom L, Nilsson S, et al. (2015) The GH receptor exon 3 deleted/full-length polymorphism is associated with central adiposity in the general population. J Endocrinol 172: 123–128. doi: 10.1530/JEJ-14-0723 PMID: 25391539.

32. Mulhall J, Hegele RA, Cao H, Hertzano R, Ben-David O, Bell RE, et al. (2003) Multiple mutations of MYO1A, a cochlear-expressed gene, in sensorineural hearing loss. Am J Hum Genet 72: 1571–1577. PMID: 12736868.

33. Tyska MJ, Mackey AT, Huang JD, Copeland NG, Jenkins NA, Moosker MS. (2005) Myosin-1a is critical for normal brush border structure and composition. Mol Biol Cell 16: 2443–2457. PMID: 15758024.
35. Eisenberger T, Di Donato N, Baig SM, Neuhaus C, Beyer A, Decker E, et al. (2014) Targeted and Genome-wide NGS Data Disqualify Mutations in MYO1A, the "DFNA48 Gene", as a Cause of Deafness. Hum Mutat 35: 565–570. doi: 10.1002/humu.22532 PMID: 24616153

36. Bartke A (2003) Can growth hormone (GH) accelerate aging? Evidence from GH-transgenic mice. Neuroendocrinology 78: 210–216. PMID: 14583653

37. Brown-Borg HM, Borg KE, Meliska CJ, Bartke A (1996) Dwarf mice and the ageing process. Nature 384: 33. PMID: 8900273

38. Coschigano KT, Holland AN, Riders ME, List EO, Flyvbjer A, Kopchick JJ. (2003) Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology 144: 3799–3810. PMID: 12933651

39. Huebner K, Druck T, LaForgia S, Lasota J, Croce CM, Lanfrancone L, et al. (1993) Chromosomal localization of four human zinc finger cDNAs. Hum Genet 91: 217–222. PMID: 8478004

40. Feng J, Zhang Z, Wu X, Mao A, Chang F, Deng X, et al. (2013) Discovery of potential new gene variants and inflammatory cytokine associations with fibromyalgia syndrome by whole exome sequencing. PLoS One 8: e65033. doi: 10.1371/journal.pone.0065033 PMID: 23762283

41. Bozzola M, De Benedetti F, De Amici M, Jouret B, Travaglino P, Pagani S, et al. (2003) Stimulating effect of growth hormone on cytokine release in children. Eur J Endocrinol 149: 397–401. PMID: 14585084

42. Pagani S, Meazza C, Travaglino P, De Benedetti F, Tinelli C, Bozzola M. (2005) Serum cytokine levels in GH-deficient children during substitutive GH therapy. Eur J Endocrinol 152: 207–210. PMID: 15745927